What the Research Says on K2 vs K1 for Bones
Vitamin K2 shows stronger evidence for improving bone health compared to K1. K2 activates osteocalcin, a protein that binds calcium to bones, increasing bone mineral density and reducing fracture risk. Studies, including a 3-year trial of 244 postmenopausal women, found K2 (45 mg/day menaquinone-7) raised bone density by 1-3% while slowing loss in the placebo group.[1] A meta-analysis of 6 randomized trials confirmed K2 reduces bone loss, particularly in older women.[2]
K1, mainly from greens, supports basic carboxylation but doesn't concentrate as well in bones. Trials like the Framingham Heart Study linked higher K1 intake to lower hip fracture risk, but effects were weaker and inconsistent.[3] Head-to-head comparisons are limited, but K2's longer half-life (days vs hours for K1) and better tissue distribution give it an edge for bones.[4]
How They Work Differently in the Body
Both vitamins carboxylate proteins, but K2 targets bone-specific ones like osteocalcin and matrix Gla protein (MGP), inhibiting arterial calcification while directing calcium to bones. K1 prioritizes liver clotting factors and circulates less to extrahepatic tissues.[5] Animal studies show K2 restores bone structure in vitamin K-deficient rats, unlike K1.[6]
Food Sources and Typical Doses
K1 comes from leafy greens (kale, spinach: 100-1000 mcg/serving). K2 is in fermented foods (natto: 1000 mcg/100g), cheese, and egg yolks (10-50 mcg/serving).[7] Supplements use K2 forms like MK-4 (1-45 mg) or MK-7 (100-200 mcg). Trials favor higher K2 doses for bones; standard multivitamins often provide just 100 mcg K1.
Who Might Benefit Most from K2
Postmenopausal women and those with osteoporosis see the biggest gains—up to 80% fracture risk drop in some Japanese studies with MK-4.[8] K2 pairs well with vitamin D and calcium. K1 suffices for general needs if diet is green-heavy, but K2 fills gaps for bone-focused support. No major risks at studied doses, though warfarin users should avoid high amounts.[9]
Potential Downsides and Gaps in Evidence
K2 lacks massive long-term trials versus drugs like bisphosphonates. Some studies show no fracture benefit despite density gains.[10] K1 is cheaper and easier from diet. Observational data ties total K intake to bones, but causation isn't ironclad for either.
[1] Knapen et al., Osteoporos Int (2013)
[2] Huang et al., PLoS One (2015)
[3] Booth et al., J Bone Miner Res (2000)
[4] Schurgers et al., Blood (2007)
[5] Shearer & Newman, Nutr Rev (2014)
[6] Halcrow et al., Calcif Tissue Int (1987)
[7] Elder et al., Nutr Rev (2006)
[8] Shiraki et al., J Bone Miner Res (2000)
[9] Holzherr et al., Thromb Haemost (2012)
[10] Cockayne et al., Arch Intern Med (2006)